Last reviewed · How we verify

Fibrinogen + PCC — Competitive Intelligence Brief

Fibrinogen + PCC (Fibrinogen + PCC) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hemostatic agent / Coagulation factor replacement. Area: Hematology / Critical Care / Hemostasis.

marketed Hemostatic agent / Coagulation factor replacement Hematology / Critical Care / Hemostasis Biologic Live · refreshed every 30 min

Target snapshot

Fibrinogen + PCC (Fibrinogen + PCC) — University Health Network, Toronto. This combination replaces depleted fibrinogen and restores multiple clotting factors simultaneously to correct severe coagulopathy and promote hemostasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fibrinogen + PCC TARGET Fibrinogen + PCC University Health Network, Toronto marketed Hemostatic agent / Coagulation factor replacement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hemostatic agent / Coagulation factor replacement class)

  1. University Health Network, Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fibrinogen + PCC — Competitive Intelligence Brief. https://druglandscape.com/ci/fibrinogen-pcc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: